NCT07737054 Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD
| NCT ID | NCT07737054 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Condition | Post-Traumatic Stress Disorder, PTSD |
| Study Type | INTERVENTIONAL |
| Enrollment | 13 participants |
| Start Date | 2025-07-22 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 13 participants in total. It began in 2025-07-22 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an open-label pilot study designed to evaluate the safety, tolerability, and preliminary clinical effects of psilocybin-enhanced trauma-focused psychotherapy in individuals with post-traumatic stress disorder (PTSD). Participants will receive a structured therapeutic protocol that includes preparatory sessions, two psilocybin administration sessions (15 mg followed by 25 mg), and integration sessions based on a trauma-focused therapeutic approach. The primary objective of the study is to assess the safety and tolerability of psilocybin administration in this clinical population. Secondary objectives include evaluating changes in PTSD symptom severity, as measured by the Clinician-Administered PTSD Scale (CAPS-5), at 30 days following treatment. This pilot study will include 13 participants and is intended to inform the feasibility and design of a subsequent randomized controlled trial.
Eligibility Criteria
Inclusion Criteria: * Age 21-65 years. * Diagnosis of post-traumatic stress disorder (PTSD) according to DSM-5 criteria, as assessed by CAPS-5. * At least 1 year since the traumatic event. * Moderate or greater PTSD severity (CAPS-5 score ≥ 25). * Ability to provide written informed consent. * Ability to read, write, speak, and understand Hebrew. * Prior trauma-focused psychotherapy. * Medically healthy at screening, as determined by a study physician, including: * No exclusionary medical conditions. * Resting blood pressure between 90/60 and 150/90 mmHg and heart rate between 45-100 bpm. * Normal laboratory results (including liver function, renal function, and electrolytes). Exclusion Criteria: * Current or past diagnosis of psychotic disorders, bipolar disorder, schizoaffective disorder, dissociative identity disorder, or borderline personality disorder (as assessed by MINI or SCID-5-SPQ). * Current psychotic features. * First-degree relative with a history of a psychotic disorder. * History of antidepressant-induced mania or hypomania. * Significant suicidal risk as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS), including active suicidal ideation with intent or plan, or suicidal behavior within the past 6 months. * Substance use disorder (excluding nicotine and caffeine); mild-to-moderate alcohol or cannabis use may be permitted under monitoring and PI approval. * Use of psychedelic substances within 3 months before enrollment * Participation in a clinical trial involving administration of a psychedelic substance within the past 12 months. * History of adverse psychological reaction to psychedelics requiring hospitalization. * Significant cardiovascular disease, including ischemic heart disease, uncontrolled hypertension, arrhythmia, or heart failure (NYHA class ≥3). * Dementia or suspected cognitive impairment. * Traumatic brain injury with loss of consciousness \>24 hours or post-traumatic amnesia \>7 days (unless cleared by neurological evaluation). * Pregnancy, breastfeeding, or positive pregnancy/drug test (excluding cannabis) on the day of dosing. * BMI \<18 or \>33 * Abnormal liver or renal function tests. * Use of medications contraindicated with psilocybin. * Changes in psychiatric medication (dose or type) within one month before enrollment. * Needle phobia or inability to undergo blood testing.
Contact & Investigator
Talma Hendler, Prof.
PRINCIPAL INVESTIGATOR
Tel Aviv University and Tel Aviv Sourasky Medical Center
Frequently Asked Questions
Who can join the NCT07737054 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 65 Years, studying Post-Traumatic Stress Disorder, PTSD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07737054 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07737054 currently recruiting?
Yes, NCT07737054 is actively recruiting participants. Contact the research team at ayeletorb@gmail.com for enrollment information.
Where is the NCT07737054 trial being conducted?
This trial is being conducted at Tel Aviv, Israel.
Who is sponsoring the NCT07737054 clinical trial?
NCT07737054 is sponsored by Tel-Aviv Sourasky Medical Center. The principal investigator is Talma Hendler, Prof. at Tel Aviv University and Tel Aviv Sourasky Medical Center. The trial plans to enroll 13 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.